Standard BioTools Inc

LAB

0.929USD

-0.029-3.01%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Standard BioTools Inc's Score

Industry at a Glance

Industry Ranking

86 / 208

Overall Ranking

213 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Standard BioTools Inc Highlights

StrengthsRisks

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Growing

The company is in a growing phase, with the latest annual income totaling USD 85.33M.

Undervalued

The company’s latest PE is -4.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 297.38M shares, decreasing 8.74% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 39.53K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.65.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

1.550

Target Price

+61.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Standard BioTools Inc is 6.73, ranking 120 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 23.80M, representing a year-over-year decrease of 49.07%, while its net profit experienced a year-over-year decrease of 156.59%.

Score

Industry at a Glance

Previous score

6.73

Change

0



Financials

8.59

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.59

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.09

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Standard BioTools Inc is 7.10, ranking 123 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -4.57, which is -88.29% below the recent high of -0.54 and -30.39% above the recent low of -5.96.

Score

Industry at a Glance

Previous score

7.10

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 86/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Standard BioTools Inc is 7.33, ranking 134 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 1.55, with a high of 1.75 and a low of 1.35.

Score

Industry at a Glance

Previous score

7.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Standard BioTools Inc is 6.26, ranking 147 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.08 and the support level at 0.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Standard BioTools Inc is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 77.33%, representing a quarter-over-quarter increase of 6.97%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 58.65M shares, representing 15.04% of shares outstanding, with 2.63% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Casdin Capital, LLC

88.78M

+0.40%

Viking Global Investors LP

Star Investors

58.65M

--

BlackRock Institutional Trust Company, N.A.

21.81M

+0.09%

MAK Capital One, LLC

15.93M

+184.63%

The Vanguard Group, Inc.

Star Investors

17.19M

+1.56%

Long Focus Capital Management LLC

11.36M

+12.84%

Geode Capital Management, L.L.C.

7.47M

+0.37%

Morgan Stanley Investment Management Inc. (US)

5.64M

+5.33%

State Street Investment Management (US)

6.40M

+1.61%

Hollow Brook Wealth Management, LLC

5.78M

+2.95%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Standard BioTools Inc is 3.91, ranking 117 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Standard BioTools Inc

LAB

6.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment